The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Dihexa in Clinical Trials: What We've Learned So Far CDER Brings Many Safe and Effective Therapies to Patients and Consumers in 2024 FDA The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like Peptides: FDA Approved vs Research Peptides Not all peptides are created equal Some are FDA approved medications with real clinical data, regulated manufacturing, and proven safety. Others are sold online as